Please use this identifier to cite or link to this item:
http://hdl.handle.net/11375/29635
Title: | Temperate Phage-Antibiotic Synergy |
Authors: | Al-Anany, Amany |
Advisor: | Hynes, Alexander |
Department: | Biochemistry and Biomedical Sciences |
Keywords: | Phage therapy;Temperate phage;Antibiotic |
Publication Date: | 2024 |
Abstract: | The escalating threat of antimicrobial resistance has intensified the exploration of alternative treatments, with bacteriophage (phage) therapy emerging as a potential substitute for antibiotics. While strictly lytic phages rapidly kill bacteria, temperate phages can also go dormant in their hosts. Accordingly, despite their prevalence, they are considered unsuitable for therapy. My systematic review of phage therapy in urinary tract infections (UTIs) highlighted this. This review motivated me to explore how the potential of these phages could be leveraged. Chapter 3 introduces a novel strategy to do so, exploring whether the fluoroquinolone antibiotic ciprofloxacin could synergize with temperate phages. This innovative strategy exploits the ability of the antibiotic to awaken dormant temperate phages, driving a potent synergy (≥8 log reduction) able to result in bacterial eradication. This is a potential breakthrough in the use of phages. Chapter 4 expands on this finding, establishing that a synergy exists across various drug classes with diverse mechanisms of action. Surprisingly, the synergy extends beyond antibiotics triggering the bacterial SOS-response known to wake temperate phages and also includes protein synthesis inhibitors, offering a new approach to influence the phage lysis-lysogeny decision. Chapter 5 explores the identified synergy in antibiotic-resistant models, focusing on the impact of antibiotic resistance on the effect of combining temperate phages with antibiotics. While the majority of cases demonstrated synergy comparable to the absence of antibiotic resistance, an exception was noted in the acetylation-resistant models for both gentamicin and ciprofloxacin. These resistance genes abolished synergy with the temperate phage, emphasizing the importance of the resistance mechanism within temperate phage antibiotic synergy (tPAS). In conclusion, this thesis underscores the lack of interest in temperate phages for therapy and demonstrates a scalable strategy to overcome the major barriers to their use. I uncover the mechanisms underlying the synergy and show that these concepts are applicable even in the context of resistance to the synergizing antibiotic. These findings propose a remarkable shift in how antimicrobial therapy approaches are viewed. |
URI: | http://hdl.handle.net/11375/29635 |
Appears in Collections: | Open Access Dissertations and Theses |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Amany_Alanany 202404.pdf | 9.38 MB | Adobe PDF | View/Open |
Items in MacSphere are protected by copyright, with all rights reserved, unless otherwise indicated.